Xiaoyan N. Yang

172 Tongzipo Road
Changsha, 410013, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A randomized controlled phase Ia clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of tofacitinib tartrate cream (HZ-J001) in healthy Chinese subjects.

A randomized controlled phase Ia clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of tofacitinib tartrate cream (HZ-J001) in healthy Chinese subjects.

Journal: Frontiers in pharmacology

Published: March 03, 2026

Safety, pharmacokinetics, and sex hormone suppression of LY01021 versus relugolix: A single- and multiple-dose escalation study.

Safety, pharmacokinetics, and sex hormone suppression of LY01021 versus relugolix: A single- and multiple-dose escalation study.

Journal: European journal of pharmacology

Published: September 02, 2025

Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects.

Journal: Research and practice in thrombosis and haemostasis

Published: May 06, 2025

Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial.

Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial.

Journal: Expert opinion on investigational drugs

Published: December 16, 2024

Inflammatory Factors and Immune Cells in Relation to Multiple Myeloma.

Inflammatory Factors and Immune Cells in Relation to Multiple Myeloma.

Journal: Acta haematologica

Published: April 22, 2024

Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling.

Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling.

Journal: The AAPS journal

Published: March 29, 2024

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects.

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects.

Journal: Drug design, development and therapy

Published: April 26, 2023

Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.

Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: March 21, 2023

Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.

Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.

Journal: Expert opinion on investigational drugs

Published: September 16, 2022

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.

Journal: Expert opinion on investigational drugs

Published: August 31, 2022

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects.

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects.

Journal: Frontiers in pharmacology

Published: May 26, 2022

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

Journal: Cancer medicine

Published: March 02, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026